Bioactive Products
| A unique collection of 267 Inhibitor natural compounds | ||
| Catalog No: | Bb221 | Inhibitors Compound Library Screening Details |
| Size: | 1mg/well * 267 Compounds 2mg/well * 267 Compounds | |
| Cat. No. | Information |
| CFN98544 | Cinobufagin Cinobufagin, a kind of Chinese materia medica with antitumor effect, is widely used in clinical practice, especially in anti-liver cancer, it also has anti-hepatitis B virus activity . Cinobufagin inhibits the proliferation and induces apoptosis, may be related to the mitochondria-mediated pathway and GSK-3β/NF-κB pathway. Cinobufagin can significantly relieve cancer pain in mice and raised their pain threshold, mainly upregulating the expression levels of β -END and μ -OR in the hind paw tumor and adjacent tissue.Cinobufagin and bufalin exhibit cardiotonic and natriuretic activities, they also have inhibitory effects on steroidogenesis of aldosterone and cortisol. |
| CFN98600 | Semialactone Semialactone shows inhibitory activities on human acyl-CoA:cholesterol acyltransferase(hACAT)1 with IC50 values of 79.1 uM and on human hACAT2 with IC50 values of 76.9 uM, it may be effective in the prevention and treatment of hypercholesterolemia or atherosclerosis via inhibitory effect on hACAT. |
| CFN98546 | Lithospermic acid Lithospermic acid has anti-HIV, antioxidant ,anti-inflammatory, and hepatoprotective effects, is a competitive inhibitor of xanthine oxidas (XO), can directly scavenge superoxide and inhibit superoxide production in vitro, and presents hypouricemic actions in vivo. Lithospermic acid has inhibitory effects on proliferation and migration of rat vascular smooth muscle cells, it has a preventive effect on the development of diabetic retinopathy. Lithospermic acid can attenuate 1-methyl-4-phenylpyridine-induced neurotoxicity by blocking neuronal apoptotic and neuroinflammatory pathways. Lithospermic acid can attenuate mesenteric ischemia reperfusion injury in rat intestines by increasing tissue SOD and GPx activities and decreasing MDA and MPO levels, also improves morphological alterations which occurred after periods of reperfusion. |
| CFN98603 | Naringenin triacetate Naringenin triacetate exhibits a better binding affinity with multiple crystal structures of first bromodomain BRD4 (BRD4 BD1) when compared with the known inhibitors. |
| CFN98604 | Murrangatin Murrangatin may be a valuable anti-tumor-promoting agent, it can significantly inhibit Epstein–Barr virus early antigen (EBV–EA) activation, and preserve the high viability of Raji cells, it also exhibits cytotoxicity against cholangiocarcinoma cell line, KKU-100. Murrangatin exhibits antibacterial activity against P. gingivalis (ATCC 33277). Murrangatin also shows soluble epoxide hydrolase inhibitory activity with IC50 values 13.9±6.5uM. Murrangatin and murracarpin may be a new backbone for developing inhibitors of cyclooxygenase 2, they show chondroprotective activity by downregulation of interleukin-1β, tumor necrosis factorα, prostaglandins E2,and matrix metalloproteinases -13, and both of them may be a new backbone for developing inhibitors of cyclooxygenase 2. |
